Press releases

13 December, 2017

Regulatory

NeuroVive’s KL1333 program granted orphan drug designation by the European Commission

Lund, Sweden, 13 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the compa ...

11 December, 2017

Regulatory

NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333

Lund, Sweden, 11 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' join ...

30 November, 2017

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in ...

30 November, 2017

Regulatory

NeuroVive’s genetic mitochondrial disease program NVP015 reaches significant milestone

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demons ...

21 November, 2017

Regulatory

NeuroVive Pharmaceutical AB Interim report January – September 2017

Continued positive trend for NeuroSTAT® Business operations

15 November, 2017

NeuroVive presents TBI clinical study results at Nordic Neurotrauma Conference

Lund, Sweden, 15 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic bra ...

8 November, 2017

Regulatory

NeuroVive’s Clinical Development Project KL1333 Receives Positive Opinion on European Orphan Drug Designation

Lund, Sweden, 8 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the Committee for Orphan Medicinal Products ...

7 November, 2017

Regulatory

NeuroVive Board Chair Resigns, New Chair Elected

Lund, Sweden, 7 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that Gregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective ...

3 November, 2017

Regulatory

NeuroVive conducts a directed new share issue of SEK 5.3 Million

Lund, Sweden, 3 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directe ...

31 October, 2017

Regulatory

NeuroVive signs collaboration agreement with University of Florida for TBI biomarker development

Lund, Sweden, 31 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has signed a collaboration agreement with Kevin K.W. Wang, Ph.D., of ...

18 October, 2017

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

Lund, Sweden, 18 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive and Ramin Massoumi at Lund Univers ...

5 October, 2017

NeuroVive’s collaborator the Children’s Hospital of Philadelphia awarded NIH grant to study NVP015 against chemical threats

Lund, Sweden, 5 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF, the mitochondrial medicine company, today announced that its research collaboration partner the Childre ...